This is a type of medicine used to treat certain cancers, like colorectal cancer. It works by stopping the growth of cancer cells. It's given as an injection, usually in a hospital or clinic setting.
Every report comes from a Lived member, sent anonymously.
Have you tried Irinotecan for Colorectal Cancer?
Irinotecan is an intravenous chemotherapy medicine used mainly for colorectal and pancreatic cancers that have spread beyond where they started (metastatic cancer). It comes as two distinct products with different approvals. Standard irinotecan, sold as Camptosar and as generics, is approved for metastatic colon or rectal cancer. It can be part of the first treatment, given together with fluorouracil (5-FU, another chemotherapy drug) and leucovorin (a vitamin-like drug that strengthens 5-FU's effect), or it can be used when the cancer has come back or grown after 5-FU-based treatment. It is the "IRI" in FOLFIRI, a common colorectal cancer combination, and is also one of the four drugs in FOLFIRINOX, a combination used for metastatic pancreatic cancer. Onivyde is irinotecan packed inside tiny fat-based bubbles called liposomes. It is approved only for adults with metastatic pancreatic adenocarcinoma, the most common type of pancreatic cancer, and always alongside other drugs: as a first treatment with oxaliplatin, fluorouracil and leucovorin (a combination called NALIRIFOX), or with fluorouracil and leucovorin after gemcitabine-based chemotherapy has stopped working. It is not used on its own. Irinotecan is also being studied in other cancers.
Before a cell divides, it has to copy its DNA. To do that, an enzyme called topoisomerase I makes temporary nicks in the DNA strand to relieve twisting, then reseals them. Irinotecan, and its active form SN-38 that the body makes from it, lock onto this enzyme and stop the resealing. When the cell then tries to copy its DNA, those open nicks turn into double-strand breaks the cell cannot repair, and it dies. This damage falls hardest on cells that are dividing quickly. That includes cancer cells, but also healthy cells lining the gut and the bone marrow cells that make white blood cells, which is why diarrhea and low blood counts are the drug's main side effects. The liver clears SN-38 using an enzyme called UGT1A1, so how well that enzyme works affects how strongly a person reacts. In Onivyde, the liposome coating changes how the drug travels through the body, so its doses are much lower than, and not comparable to, standard irinotecan.
Irinotecan is given as an infusion into a vein, usually over about 90 minutes, at a cancer center or infusion clinic. Doses are calculated from body size and depend on the regimen. Standard irinotecan may be given weekly for several weeks followed by a rest, every two weeks in some combination schedules, or every three weeks when used alone. Onivyde is given every two weeks, before its partner drugs. Treatment continues in cycles for as long as it is helping and side effects stay manageable. Before each infusion, people usually receive anti-nausea medicine, often with a steroid such as dexamethasone. Onivyde and standard irinotecan are not interchangeable: their doses differ greatly, and one must never be substituted for the other. The care team typically sends people home with loperamide (Imodium), an anti-diarrhea medicine, along with a specific plan for using it during treatment that differs from the package directions. Doses are often lowered, or the next cycle delayed, after severe diarrhea, low blood counts or other significant side effects. A lower starting dose may be chosen for people with certain gene variants or abnormal liver tests.
Diarrhea is the side effect that matters most, and it comes in two forms. Early diarrhea starts during or within hours of the infusion and often comes with sweating, watery eyes, a runny nose, extra saliva, flushing and stomach cramps. It is usually brief, and the infusion team can prevent or treat it with a medicine called atropine. Late diarrhea starts more than a day after treatment, often several days later, and can become severe enough to cause dehydration, dangerous shifts in blood salts or serious infection. Start loperamide at the first loose stool or the first sign of more frequent bowel movements, following the team's instructions exactly, and keep drinking fluids. Call the care team right away if diarrhea is not under control within 24 hours, if stools are black or bloody, if you feel lightheaded, dizzy or faint, or if you cannot keep fluids down. Irinotecan also lowers white blood cells, which fight infection, and infections during that time can become life-threatening. Check your temperature regularly and call the care team immediately, day or night, for a fever, chills or other signs of infection. Other common effects include nausea, vomiting, loss of appetite, tiredness, mouth sores, constipation, weight loss and hair thinning or loss. Some people feel dizzy or notice vision changes within 24 hours of an infusion. Less often, irinotecan inflames the lungs, so report a new or worsening cough or shortness of breath to the care team promptly. Severe allergic reactions are rare and usually happen during the infusion, where staff can treat them; tell the nurse at once about chest tightness, wheezing or swelling of the face or lips.
Several medicines change how much irinotecan reaches the body. St. John's wort (an herbal supplement used for mood), the seizure medicines phenytoin, phenobarbital and carbamazepine, and the tuberculosis antibiotic rifampin can sharply lower irinotecan levels, which may make treatment less effective; when possible they are switched at least two weeks before starting. Ketoconazole and some other antifungal medicines, the antibiotic clarithromycin and certain HIV medicines can raise levels and increase side effects; these are generally stopped at least a week before treatment. Give the oncology team and pharmacist a complete list, including supplements and over-the-counter products. Inherited differences in the UGT1A1 gene affect how quickly the liver clears irinotecan's active form. People who carry two copies of a reduced-function variant build up higher levels and face a greater risk of severe drops in white blood cells and of severe diarrhea. This is fairly common: roughly 1 in 10 White people and 1 in 5 Black people carry two copies of the most frequent variant. Genetic testing can identify these variants before treatment, and the starting dose may be lowered for people who have them. People with a high bilirubin level (a liver blood test) also tend to have more side effects, and above certain levels there is no established safe dose. Irinotecan can harm a developing baby. Women who could become pregnant should use effective birth control during treatment and for 6 months after the last dose of standard irinotecan (7 months for Onivyde), and men with partners who could become pregnant should use condoms for 3 months afterward (4 months for Onivyde). Breastfeeding is not recommended during treatment and for at least a week after standard irinotecan, or one month after Onivyde. Irinotecan may also reduce fertility, which is worth discussing before treatment begins. Anyone who has had a severe allergic reaction to an irinotecan product should not receive it again.
Irinotecan is given in repeating cycles. Blood counts are checked regularly (for Onivyde, on the first and eighth day of each cycle), and periodic scans show whether the cancer is responding. A cycle is postponed until diarrhea has fully settled and blood counts have recovered, and doses are often adjusted along the way. People taking Onivyde are also advised to avoid lactose-containing foods and drinks, eat small low-fat meals and stay well hydrated to lower the risk of severe diarrhea. For metastatic cancer, the goal is usually to control the disease, ease symptoms and extend life rather than to cure it. In the main trial of Onivyde as a first treatment for metastatic pancreatic cancer, people lived a median of about 11 months, compared with about 9 months on another standard combination. After gemcitabine had stopped working, adding Onivyde to fluorouracil and leucovorin extended median survival from about 4 months to about 6. These are averages across many people, and individual results vary. The first cycle is often when people learn how their body reacts. Keeping loperamide at home, tracking bowel movements and temperature, and knowing exactly how to reach the team after hours help catch problems early, when they are easier to manage.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Irinotecan, what you've noticed, or ask the community a question.